Immix Biopharma, Inc. (IMMX)
After hours:
| Previous close | 2.1300 |
| Open | 2.1300 |
| Bid | 1.9500 x 100 |
| Ask | 2.0300 x 100 |
| Day's range | 1.9600 - 2.1300 |
| 52-week range | 1.5500 - 7.7500 |
| Volume | |
| Avg. volume | 134,814 |
| Market cap | 52.3M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be
- GlobeNewswire
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond Best responder duration of response was 28.0 months with response ongoing as of May 10, 2024U.S. prevalence of relapsed/refractory AL Amyloidosis i
- GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, N
